xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05991661</url>
    </required_header>
    <id_info>
      <org_study_id>XKH001-102</org_study_id>
      <nct_id>NCT05991661</nct_id>
    </id_info>
    <brief_title>XKH001 Injection in Healthy Subjects</brief_title>
    <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XKH001 Injection in Healthy Subjects</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Beijing Kanova Biopharmaceutical Co., LTD</agency>
        <agency_class>Industry</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Suzhou Kanova Biopharmaceutical Co., LTD</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD)&#xD;
        clinical study. The primary objective is to evaluate the safety, tolerability, and PK of&#xD;
        multiple SC doses of XKH001 in healthy subjects.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        A total of 5 cohorts are planned, with 8 subjects (6 on XKH001 and 2 on placebo) in each&#xD;
        cohort. The dosing schedule for the first 3 cohorts is as follows:&#xD;
  &#xD;
        Cohort Dosing Regimen&#xD;
  &#xD;
          1. 100 mg Q4W (D1, D29, D57)&#xD;
  &#xD;
          2. 300 mg Q4W (D1, D29, D57)&#xD;
  &#xD;
          3. 600 mg Q4W (D1, D29, D57) After completion of a 6-week safety observation (D1~D43) in&#xD;
             the previous cohort, the safety data will be reviewed (blinded) by the investigator and&#xD;
             the Sponsor to assess the safety and tolerability of the investigational product. If the&#xD;
             dose regimen for the previous cohort is confirmed to be safe and tolerable, dose&#xD;
             escalation will continue to the next cohort.&#xD;
  &#xD;
        The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th&#xD;
        cohorts (e.g., 600 mg Q14D, and the specific dose regimen will be determined at that time) no&#xD;
        later than the completion of the safety assessment for Cohort 3.&#xD;
  &#xD;
        Healthy subjects will be screened within 7 days prior to the first dose and successfully&#xD;
        screened subjects will be assigned to the currently ongoing cohort and randomized to receive&#xD;
        XKH001 or placebo. Subjects will be admitted to the study site the day before each scheduled&#xD;
        dose (D-1, or D28, or D56), complete necessary pre-dose safety assessments, receive SC&#xD;
        injection of XKH001 or placebo on D1, or D29, or D57, respectively, and continue to undergo&#xD;
        regular safety assessment procedures and other blood sampling (PK, PD, and ADA) after dosing.&#xD;
  &#xD;
        Subjects will also undergo comprehensive safety assessments on D15, D43, D71, D85, D113, D141&#xD;
        and D169, including AEs/serious adverse events (SAEs), vital signs, physical examinations,&#xD;
        laboratory tests (hematology, blood chemistry, coagulation, urinalysis), 12-lead ECG, etc.&#xD;
        Safety data as of D43 will be used by the Sponsor and investigator to assess the safety and&#xD;
        tolerability of the investigational product.&#xD;
  &#xD;
        If a subject discontinues treatment prematurely, the &quot;Early Withdrawal&quot; visit and all&#xD;
        procedures will be performed as on D169.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">September 1, 2023</start_date>
    <completion_date type="Anticipated">December 1, 2024</completion_date>
    <primary_completion_date type="Anticipated">August 1, 2024</primary_completion_date>
    <phase>Phase 1/Phase 2</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Health Services Research</primary_purpose>
      <masking>Double (Participant, Investigator)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Incidence of adverse events (AEs) and serious adverse events (SAEs);</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Incidence of adverse events (AEs) and serious adverse events (SAEs);</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 1</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>general condition</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 2</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>skin and mucosa</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 3</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>lymph nodes</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 4</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>head</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 5</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>neck</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 6</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>chest</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 7</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>abdomen</description>
    </primary_outcome>
    <primary_outcome>
      <measure>laboratory tests 8</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>spine/extremities</description>
    </primary_outcome>
    <primary_outcome>
      <measure>observation of injection site</measure>
      <time_frame>2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose</time_frame>
      <description>The specific time of observation of injection site reactions is 2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Vital signs</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Vital signs include temperature, pulse, and blood pressure. Vital signs will be measured within 60 min before dosing, 2 h (± 30 min), 4 h (± 30 min) after dosing on each dosing day (D1, or D29, or D57); at other visits, vital signs should be measured once.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Hematology</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Hematology should include hemoglobin, red blood cell (RBC) count, mean corpuscular hemoglobin, mean corpuscular volume, platelet count, white blood cell (WBC) count, and absolute and percentage of NEUT, LYM, and EOS.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Blood chemistry</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Blood chemistry should include fasting glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase, total bilirubin, direct bilirubin, indirect bilirubin, gamma-glutamyl transpeptidase, creatinine, urea, sodium, potassium, calcium, inorganic phosphorus, chloride, serum lipase, and serum amylase.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Three items of thyroid function</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Three items of thyroid function should include: FT3, FT4 and TSH.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Urinalysis</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Urinalysis should include specific gravity, potential of hydrogen (pH), glucose, bilirubin, urobilinogen, protein, ketones, and occult blood.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>12-lead ECGs</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>12-lead ECGs will be performed at screening, 60 min (± 10 min), 30 min (± 10 min), 15 min (± 10 min) pre-dose on D1, 4 h (± 30 min) post-dose on D1, 4 h (± 30 min) post-dose on D15, D28, and D29, 4 h (± 30 min) post-dose on D43, D56, and D57, and on D58 (approximately 24 h), D59 (approximately 48 h), D61 (approximately 96 h), D64 (approximately 168 h), D71 (approximately 336 h), D85 (approximately 672 h), D113 (approximately 1344 h), D141 (approximately 2016 h), and D169 (approximately 2688 h); before dosing on D1, 3 ECGs should be obtained each time, with an interval of 1-2 min. ECGs from D58 to D169 should be completed within 10 min before PK blood sampling at the current visit for 3 consecutive times, with an interval of approximately 1-2 min.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Infectious disease</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Infectious disease testing should include 5 items of hepatitis B serology (hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody), hepatitis C antibody, treponema pallidum antibody, and HIV antigen/antibody. If the subject is negative for HBsAg, positive for HBcAb, and negative for HBsAb, HBV DNA testing is also required.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Anteroposterior chest X-ray</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Anteroposterior chest X-ray obtained within 3 months before screening is acceptable, and abdominal color ultrasonography obtained within 1 month before screening is acceptable.</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Cmax</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Cmax,ss（Maximum observed concentration）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Cmin</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Cmin,ss（Minimum observed concentration）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Cavg</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Cavg,ss（Mean observed concentration）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK AUC0-inf</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>AUC0-inf,ss（Area under the serum concentration-time curve from zero to infinity）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK AUC0-t</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>AUC0-t,ss（Area under the serum concentration-time curve from zero to t）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Tmax</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Tmax,ss（Time of observed）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK t1/2</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>t1/2,ss（Terminal half-life）</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK AUCtau</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>area under the serum concentration-time curve at steady state (AUCtau)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK %AUCex</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>percentage of extrapolated area under the serum concentration-time curve from zero to infinity at steady state (%AUCex)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK λz</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>elimination rate constant of serum concentration in the terminal phase (λz,ss)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Rac</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>drug accumulation ratio (Rac)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK Vz</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>volume of distribution at steady state (Vz,ss/F)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK CL</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>clearance at steady state (CLss/F)</description>
    </primary_outcome>
    <primary_outcome>
      <measure>PK MRT</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>mean residence time (MRT)</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Total IgE;</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Total Immunoglobulin E（IgE）;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>EOS count in whole blood;</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Eosinophil（EOS） count in whole blood;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>NEUT count in whole blood;</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Neutrophil（NEUT） count in whole blood;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood LYM count;</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Blood Lymphocyte(LYM) count;</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Levels of IL-25-related cytokines in serum</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Levels of IL-25-related cytokines in serum (multiple cytokine panel includes: IL-25, TARC, IL-8, MIP1β, Eotaxin, CXCL1 (KC/GROα), Eotaxin-3);</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>ADA</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Incidence of anti-drug antibodies (ADAs).</description>
    </secondary_outcome>
    <other_outcome>
      <measure>QT/QTc</measure>
      <time_frame>From baseline to 24 weeks of follow-up</time_frame>
      <description>Relationship between multiple-dose serum concentrations and QTcF</description>
    </other_outcome>
    <number_of_arms>2</number_of_arms>
    <enrollment type="Anticipated">40</enrollment>
    <condition>Asthma</condition>
    <arm_group>
      <arm_group_label>XKH001 Injection</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>XKH001 Placebo Injection</arm_group_label>
      <arm_group_type>Placebo Comparator</arm_group_type>
      <description>Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.</description>
    </arm_group>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>XKH001 Injection</intervention_name>
      <description>100mg/ml，1ml/vial</description>
      <arm_group_label>XKH001 Injection</arm_group_label>
      <other_name>XKH001</other_name>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>XKH001 Placebo Injection</intervention_name>
      <description>1ml/vial</description>
      <arm_group_label>XKH001 Placebo Injection</arm_group_label>
      <other_name>XKH001 Placebo</other_name>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Healthy subjects who voluntarily sign a written informed consent form (ICF) and are&#xD;
               able to complete the study as required by the protocol;&#xD;
  &#xD;
            2. Male or female subjects aged 18 to 65 years (inclusive);&#xD;
  &#xD;
            3. Subjects with BMI between 18 and 28 kg/m2 (inclusive);&#xD;
  &#xD;
            4. Subjects with normal or abnormal but not clinically significant results of vital&#xD;
               signs, physical examinations, laboratory tests, 12-lead ECGs and QTcF ≤ 450 ms;&#xD;
  &#xD;
            5. Subjects who did not use any prescription or over-the-counter medications within two&#xD;
               weeks prior to dosing;&#xD;
  &#xD;
            6. Subjects who agree to have no child-bearing plans and to voluntarily take effective&#xD;
               contraception measures during the study and within 6 months after the end of the&#xD;
               study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Pregnant or lactating women;&#xD;
  &#xD;
            2. Subjects with clinically significant diseases that may affect the subject's&#xD;
               participation in this study within 5 years as judged by the investigator: including&#xD;
               but not limited to gastrointestinal, renal, liver, lung, neurological, blood,&#xD;
               endocrine, tumor, metabolic, psychiatric or cardio-cerebrovascular diseases, etc.;&#xD;
  &#xD;
            3. Subjects with history of autoimmune diseases, known family history of inherited&#xD;
               immunodeficiency disorders, or recurrent infections suggestive of possible&#xD;
               immunodeficiency;&#xD;
  &#xD;
            4. Subjects with active infections requiring hospitalization or IV antibiotic treatment&#xD;
               within 3 months prior to dosing, or bacterial, viral and fungal infections with&#xD;
               clinical symptoms within 1 week;&#xD;
  &#xD;
            5. Subjects with a history of active tuberculosis or subjects with active or latent&#xD;
               tuberculosis infection at screening;&#xD;
  &#xD;
            6. Subjects with positive HBsAg in 5 items of hepatitis B serology (if HBsAg is negative,&#xD;
               HBcAb is positive, and HBsAb is negative, HBV DNA quantitative test is required to be&#xD;
               performed [the subject will be excluded if the test result is positive]), positive&#xD;
               hepatitis C antibody, treponema pallidum antibody, HIV antigen/antibody;&#xD;
  &#xD;
            7. Subjects who plan to receive live or live attenuated vaccines within 4 weeks prior to&#xD;
               dosing or during the study;&#xD;
  &#xD;
            8. Subjects who have participated in clinical studies of any drug or device within 3&#xD;
               months or 5 half-lives of the investigational product (whichever is longer) prior to&#xD;
               dosing;&#xD;
  &#xD;
            9. Subjects who are allergic to the investigational product or any component of the&#xD;
               formulation of the investigational product or have a history of allergy to protein&#xD;
               drugs;&#xD;
  &#xD;
           10. Subjects who have consumed more than 14 units of alcohol per week (1 unit of alcohol =&#xD;
               360 mL of beer or 45 mL of spirits containing 40% alcohol or 150 mL of wine) within 6&#xD;
               weeks prior to screening or have taken alcoholic products 1 day before dosing;&#xD;
  &#xD;
           11. Subjects who have a history of abuse of other drugs within 5 years prior to screening,&#xD;
               or who have a positive urine drug screen result;&#xD;
  &#xD;
           12. Subjects who have a smoking history (&gt; 5 cigarettes/day) within 3 months prior to&#xD;
               screening;&#xD;
  &#xD;
           13. Subjects who have blood donation or blood loss of more than 450 mL within 8 weeks&#xD;
               prior to screening, or blood donation of more than 200 mL or blood loss of more than&#xD;
               300 mL within 1 month;&#xD;
  &#xD;
           14. Subjects with obstructed venous access or intolerance to venipuncture;&#xD;
  &#xD;
           15. Subjects who are considered inappropriate for the study by the investigator.&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Yanhua Ding</last_name>
      <role>Principal Investigator</role>
      <affiliation>The First Hospital of Jilin University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Jianguo You, MHA</last_name>
      <phone>010-82176552</phone>
      <email>jianguo.you@kanovabiopharma.com</email>
    </overall_contact>
    <verification_date>March 2023</verification_date>
    <study_first_submitted>July 24, 2023</study_first_submitted>
    <study_first_submitted_qc>August 7, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 14, 2023</study_first_posted>
    <last_update_submitted>August 13, 2023</last_update_submitted>
    <last_update_submitted_qc>August 13, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 15, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05991661
  org study id: XKH001-102
  nct id: NCT05991661
  lead sponsor: 
  has dmc: No
  is fda regulated drug: Yes
  is fda regulated device: No
  This study is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD)
        clinical study. The primary objective is to evaluate the safety, tolerability, and PK of
        multiple SC doses of XKH001 in healthy subjects.
  A total of 5 cohorts are planned, with 8 subjects (6 on XKH001 and 2 on placebo) in each
        cohort. The dosing schedule for the first 3 cohorts is as follows:
  
        Cohort Dosing Regimen
  
          1. 100 mg Q4W (D1, D29, D57)
  
          2. 300 mg Q4W (D1, D29, D57)
  
          3. 600 mg Q4W (D1, D29, D57) After completion of a 6-week safety observation (D1~D43) in
             the previous cohort, the safety data will be reviewed (blinded) by the investigator and
             the Sponsor to assess the safety and tolerability of the investigational product. If the
             dose regimen for the previous cohort is confirmed to be safe and tolerable, dose
             escalation will continue to the next cohort.
  
        The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th
        cohorts (e.g., 600 mg Q14D, and the specific dose regimen will be determined at that time) no
        later than the completion of the safety assessment for Cohort 3.
  
        Healthy subjects will be screened within 7 days prior to the first dose and successfully
        screened subjects will be assigned to the currently ongoing cohort and randomized to receive
        XKH001 or placebo. Subjects will be admitted to the study site the day before each scheduled
        dose (D-1, or D28, or D56), complete necessary pre-dose safety assessments, receive SC
        injection of XKH001 or placebo on D1, or D29, or D57, respectively, and continue to undergo
        regular safety assessment procedures and other blood sampling (PK, PD, and ADA) after dosing.
  
        Subjects will also undergo comprehensive safety assessments on D15, D43, D71, D85, D113, D141
        and D169, including AEs/serious adverse events (SAEs), vital signs, physical examinations,
        laboratory tests (hematology, blood chemistry, coagulation, urinalysis), 12-lead ECG, etc.
        Safety data as of D43 will be used by the Sponsor and investigator to assess the safety and
        tolerability of the investigational product.
  
        If a subject discontinues treatment prematurely, the "Early Withdrawal" visit and all
        procedures will be performed as on D169.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Health Services Research
  masking: Double (Participant, Investigator)
  measure: Incidence of adverse events (AEs) and serious adverse events (SAEs);
  time frame: From baseline to 24 weeks of follow-up
  description: Incidence of adverse events (AEs) and serious adverse events (SAEs);
  measure: laboratory tests 1
  time frame: From baseline to 24 weeks of follow-up
  description: general condition
  measure: laboratory tests 2
  time frame: From baseline to 24 weeks of follow-up
  description: skin and mucosa
  measure: laboratory tests 3
  time frame: From baseline to 24 weeks of follow-up
  description: lymph nodes
  measure: laboratory tests 4
  time frame: From baseline to 24 weeks of follow-up
  description: head
  measure: laboratory tests 5
  time frame: From baseline to 24 weeks of follow-up
  description: neck
  measure: laboratory tests 6
  time frame: From baseline to 24 weeks of follow-up
  description: chest
  measure: laboratory tests 7
  time frame: From baseline to 24 weeks of follow-up
  description: abdomen
  measure: laboratory tests 8
  time frame: From baseline to 24 weeks of follow-up
  description: spine/extremities
  measure: observation of injection site
  time frame: 2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose
  description: The specific time of observation of injection site reactions is 2 h (± 30 min) post-dose and 4 h (± 30 min) post-dose.
  measure: Vital signs
  time frame: From baseline to 24 weeks of follow-up
  description: Vital signs include temperature, pulse, and blood pressure. Vital signs will be measured within 60 min before dosing, 2 h (± 30 min), 4 h (± 30 min) after dosing on each dosing day (D1, or D29, or D57); at other visits, vital signs should be measured once.
  measure: Hematology
  time frame: From baseline to 24 weeks of follow-up
  description: Hematology should include hemoglobin, red blood cell (RBC) count, mean corpuscular hemoglobin, mean corpuscular volume, platelet count, white blood cell (WBC) count, and absolute and percentage of NEUT, LYM, and EOS.
  measure: Blood chemistry
  time frame: From baseline to 24 weeks of follow-up
  description: Blood chemistry should include fasting glucose, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), lactate dehydrogenase, total bilirubin, direct bilirubin, indirect bilirubin, gamma-glutamyl transpeptidase, creatinine, urea, sodium, potassium, calcium, inorganic phosphorus, chloride, serum lipase, and serum amylase.
  measure: Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).
  time frame: From baseline to 24 weeks of follow-up
  description: Hematology includes: activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT).
  measure: Three items of thyroid function
  time frame: From baseline to 24 weeks of follow-up
  description: Three items of thyroid function should include: FT3, FT4 and TSH.
  measure: Urinalysis
  time frame: From baseline to 24 weeks of follow-up
  description: Urinalysis should include specific gravity, potential of hydrogen (pH), glucose, bilirubin, urobilinogen, protein, ketones, and occult blood.
  measure: 12-lead ECGs
  time frame: From baseline to 24 weeks of follow-up
  description: 12-lead ECGs will be performed at screening, 60 min (± 10 min), 30 min (± 10 min), 15 min (± 10 min) pre-dose on D1, 4 h (± 30 min) post-dose on D1, 4 h (± 30 min) post-dose on D15, D28, and D29, 4 h (± 30 min) post-dose on D43, D56, and D57, and on D58 (approximately 24 h), D59 (approximately 48 h), D61 (approximately 96 h), D64 (approximately 168 h), D71 (approximately 336 h), D85 (approximately 672 h), D113 (approximately 1344 h), D141 (approximately 2016 h), and D169 (approximately 2688 h); before dosing on D1, 3 ECGs should be obtained each time, with an interval of 1-2 min. ECGs from D58 to D169 should be completed within 10 min before PK blood sampling at the current visit for 3 consecutive times, with an interval of approximately 1-2 min.
  measure: Infectious disease
  time frame: From baseline to 24 weeks of follow-up
  description: Infectious disease testing should include 5 items of hepatitis B serology (hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody), hepatitis C antibody, treponema pallidum antibody, and HIV antigen/antibody. If the subject is negative for HBsAg, positive for HBcAb, and negative for HBsAb, HBV DNA testing is also required.
  measure: Anteroposterior chest X-ray
  time frame: From baseline to 24 weeks of follow-up
  description: Anteroposterior chest X-ray obtained within 3 months before screening is acceptable, and abdominal color ultrasonography obtained within 1 month before screening is acceptable.
  measure: PK Cmax
  time frame: From baseline to 24 weeks of follow-up
  description: Cmax,ss（Maximum observed concentration）
  measure: PK Cmin
  time frame: From baseline to 24 weeks of follow-up
  description: Cmin,ss（Minimum observed concentration）
  measure: PK Cavg
  time frame: From baseline to 24 weeks of follow-up
  description: Cavg,ss（Mean observed concentration）
  measure: PK AUC0-inf
  time frame: From baseline to 24 weeks of follow-up
  description: AUC0-inf,ss（Area under the serum concentration-time curve from zero to infinity）
  measure: PK AUC0-t
  time frame: From baseline to 24 weeks of follow-up
  description: AUC0-t,ss（Area under the serum concentration-time curve from zero to t）
  measure: PK Tmax
  time frame: From baseline to 24 weeks of follow-up
  description: Tmax,ss（Time of observed）
  measure: PK t1/2
  time frame: From baseline to 24 weeks of follow-up
  description: t1/2,ss（Terminal half-life）
  measure: PK AUCtau
  time frame: From baseline to 24 weeks of follow-up
  description: area under the serum concentration-time curve at steady state (AUCtau)
  measure: PK %AUCex
  time frame: From baseline to 24 weeks of follow-up
  description: percentage of extrapolated area under the serum concentration-time curve from zero to infinity at steady state (%AUCex)
  measure: PK λz
  time frame: From baseline to 24 weeks of follow-up
  description: elimination rate constant of serum concentration in the terminal phase (λz,ss)
  measure: PK Rac
  time frame: From baseline to 24 weeks of follow-up
  description: drug accumulation ratio (Rac)
  measure: PK Vz
  time frame: From baseline to 24 weeks of follow-up
  description: volume of distribution at steady state (Vz,ss/F)
  measure: PK CL
  time frame: From baseline to 24 weeks of follow-up
  description: clearance at steady state (CLss/F)
  measure: PK MRT
  time frame: From baseline to 24 weeks of follow-up
  description: mean residence time (MRT)
  measure: Total IgE;
  time frame: From baseline to 24 weeks of follow-up
  description: Total Immunoglobulin E（IgE）;
  measure: EOS count in whole blood;
  time frame: From baseline to 24 weeks of follow-up
  description: Eosinophil（EOS） count in whole blood;
  measure: NEUT count in whole blood;
  time frame: From baseline to 24 weeks of follow-up
  description: Neutrophil（NEUT） count in whole blood;
  measure: Blood LYM count;
  time frame: From baseline to 24 weeks of follow-up
  description: Blood Lymphocyte(LYM) count;
  measure: Levels of IL-25-related cytokines in serum
  time frame: From baseline to 24 weeks of follow-up
  description: Levels of IL-25-related cytokines in serum (multiple cytokine panel includes: IL-25, TARC, IL-8, MIP1β, Eotaxin, CXCL1 (KC/GROα), Eotaxin-3);
  measure: ADA
  time frame: From baseline to 24 weeks of follow-up
  description: Incidence of anti-drug antibodies (ADAs).
  measure: QT/QTc
  time frame: From baseline to 24 weeks of follow-up
  description: Relationship between multiple-dose serum concentrations and QTcF
  arm group label: XKH001 Injection
  arm group type: Active Comparator
  description: Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
  arm group label: XKH001 Placebo Injection
  arm group type: Placebo Comparator
  description: Cohort 1: 100 mg Q4W (D1, D29, D57) 6subjects Cohort 2: 300 mg Q4W (D1, D29, D57) 6subjects Cohort 3: 600 mg Q4W (D1, D29, D57) 6subjects The Sponsor will discuss with the investigator to decide whether to conduct the 4th to 5th cohorts (e.g., 600 mg Q14D, 600 mg Q8W, and the specific dose regimen will be determined at that time) no later than the completion of the safety assessment for Cohort 3.
  intervention type: Drug
  intervention name: XKH001 Injection
  description: 100mg/ml，1ml/vial
  arm group label: XKH001 Injection
  other name: XKH001
  intervention type: Drug
  intervention name: XKH001 Placebo Injection
  description: 1ml/vial
  arm group label: XKH001 Placebo Injection
  other name: XKH001 Placebo
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: 65 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Yanhua Ding
  role: Principal Investigator
  affiliation: The First Hospital of Jilin University
  last name: Jianguo You, MHA
  phone: 010-82176552
  email: jianguo.you@kanovabiopharma.com
  responsible party type: Sponsor
  sharing ipd: No